Dynacq Healthcare (DYII) 0.0600 $DYII CEMEKC, Inc.

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Dynacq Healthcare (DYII) 0.0600 $DYII

CEMEKC, Inc. Extends Tender Offer For Dynacq Healthcare, Inc.
PR Newswire - Fri Jan 22, 3:24PM CST
CEMEKC, Inc. (the "Purchaser" announced today that it is extending the previously announced tender offer to purchase all of the outstanding shares of Common Stock of Dynacq Healthcare, Inc. ("Dynacq" not already owned by Dr. Eric K. Chan, Ella Y. T. C. Chan, the Chiu M. Chan Family Trust and the Purchaser for $0.10 in cash per share (the "Offer" as detailed in its Schedule TO, originally filed on December 18, 2015. As a result of the waiver of the Majority-of-the-Minority Condition and the 90% Condition, the Purchaser is extending the Offer in order to provide additional time for stockholders to consider the terms as set forth in the Offer to Purchase.

CEMEKC, Inc. Announces Expiration Of Tender Offer For Dynacq Healthcare, Inc.
PR Newswire - Thu Jan 21, 7:01AM CST
CEMEKC, Inc. (the "Purchaser" announced today that it will file Amendment No. 3 to its Schedule TO, originally filed on December 18, 2015, with respect to the previously announced tender offer to purchase all of the outstanding shares of Common Stock of Dynacq Healthcare, Inc. ("Dynacq" not already owned by Dr. Eric K. Chan, Ella Y. T. C. Chan, the Chiu M. Chan Family Trust and the Purchaser for $0.10 in cash per share (the "Offer" .

CEMEKC, Inc. Announces Filing Of Amendment No. 2 To Its Schedule TO
PR Newswire - Fri Jan 08, 3:33PM CST
CEMEKC, Inc. (the "Purchaser" announced today that it will file Amendment No. 2 to its Schedule TO, originally filed on December 18, 2015, with respect to the previously announced tender offer to purchase all of the outstanding shares of Common Stock of Dynacq Healthcare, Inc. ("Dynacq" not already owned by Dr. Eric K. Chan, Ella Y. T. C. Chan, the Chiu M. Chan Family Trust and the Purchaser for $0.10 in cash per share (the "Offer" .

CEMEKC, Inc. Commences Tender Offer To Purchase Remaining Public Stake In Dynacq Healthcare, Inc.
PR Newswire - Fri Dec 18, 10:03AM CST
CEMEKC, Inc. ("Purchaser" announced today that it has commenced a tender offer to purchase all of the outstanding shares of Common Stock of Dynacq Healthcare, Inc. not already owned by Dr. Eric K. Chan, Ella Y. T. C. Chan, the Chiu M. Chan Family Trust and Purchaser for $0.10 in cash per share.

United States Outpatient Care Centers Industry Analytics 2014-2021 - Extensive Financial Benchmarks, Metrics and Revenue Forecasts - Market to reach $169.3 billion by 2021
M2 - Mon Dec 15, 8:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/wxgmv7/outpatient_care) has announced the addition of Plunkett Research Ltd's new report "Outpatient Care Centers Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Outpatient Care Centers Industry (U.S.) to reach $169.3 billion by 2021 Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked - Advanzeon Solutions Inc - AmSurg Corp - DaVita Healthcare Partners Inc - Dynacq Healthcare Inc - Fresenius Medical Care Holdings Inc - Graymark Healthcare Inc - IntegraMed America Inc - LCA-Vision Inc - United Surgical Partners International Inc For more information visit http://www.researchandmarkets.com/research/wx...tient_care Source: Plunkett Research Ltd
AMSG: 78.66 (+2.26)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 17

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 311

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 208

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 35

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 68

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 106

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 147

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 0

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 113

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Preeclampsia: Key Insights for Expecting Parents

Updated Category News Views 46

Preeclampsia: Essential Insights for Expecting Parents Preeclampsia is a significant condition that often raises concerns among expecting parents. It manifests as a dangerous form of high blood pressure during pregnancy and can also surface postpartum. Understanding this condition is vital for ensuring the health and safety of both mother and child during this crucial...

Continue Reading
DTE Energy Enhances Reliability with Smart Grid Technology

Updated Category News Views 240

DTE Energy's Progress with Smart Grid Technology DTE Energy (NYSE:DTE) has announced impressive strides in enhancing energy reliability through its cutting-edge smart grid technology. This initiative has successfully prevented nearly 5,000 power interruptions and saved over 1.8 million outage minutes for customers this year, highlighting the technology's role in ensuring...

Continue Reading
Key Insider Transactions in Major US Companies Unveiled

Updated Category News Views 270

Significant Insider Trading Activities This article sheds light on the notable insider buying and selling events reported recently, reflecting the movements within major US stocks. Major Insider Purchases Berkshire Hathaway Inc. (NYSE: BRKa) has made headlines by increasing its stake in Verisign Inc. (NASDAQ: VRSN). Under the leadership of Warren E. Buffett, the company...

Continue Reading
Hull Tactical's Latest Research Paper Enhances Market Predictions

Updated Category News Views 135

Hull Tactical Releases Innovative Academic Research The Hull Tactical team is excited to unveil its latest academic paper, titled Micro Alphas, co-authored by a talented group including Blair Hull, Petra Bakosova, Francois Cocquemas, Euan Sinclair, and Petri Fast. This research introduces a fresh framework that focuses on utilizing weak yet collectively informative...

Continue Reading
Cyrano Therapeutics and KYORIN Join Forces for Smell Loss Treatment

Updated Category News Views 138

Cyrano Therapeutics and KYORIN Collaboration Overview Cyrano Therapeutics, a pioneer in regenerative medicine, has taken a significant step forward in addressing the challenge of post-viral loss of smell. The company has entered into an option agreement with KYORIN Pharmaceutical Co., Ltd. to develop CYR-064, a promising treatment candidate specifically designed for those...

Continue Reading